vs
Side-by-side financial comparison of Incyte (INCY) and OLIN Corp (OLN). Click either name above to swap in a different company.
OLIN Corp is the larger business by last-quarter revenue ($1.6B vs $1.3B, roughly 1.2× Incyte). On growth, Incyte posted the faster year-over-year revenue change (20.9% vs -3.7%). Over the past eight quarters, Incyte's revenue compounded faster (10.4% CAGR vs -1.9%).
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Olin Corporation is an American manufacturer of ammunition, chlorine, and sodium hydroxide. The company traces its roots to two companies, both founded in 1892: Franklin W. Olin's Equitable Powder Company and the Mathieson Alkali Works. Accidents at Olin chemical plants have exposed employees and nearby residents to health hazards.
INCY vs OLN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.6B |
| Net Profit | $303.3M | — |
| Gross Margin | — | 4.8% |
| Operating Margin | 23.7% | — |
| Net Margin | 23.8% | — |
| Revenue YoY | 20.9% | -3.7% |
| Net Profit YoY | 91.7% | — |
| EPS (diluted) | $1.47 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $1.6B | ||
| Q4 25 | $1.5B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.2B | $1.8B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.2B | $1.7B | ||
| Q3 24 | $1.1B | $1.6B | ||
| Q2 24 | $1.0B | $1.6B |
| Q1 26 | $303.3M | — | ||
| Q4 25 | $299.3M | $-143.2M | ||
| Q3 25 | $424.2M | $43.7M | ||
| Q2 25 | $405.0M | $-2.8M | ||
| Q1 25 | $158.2M | $1.2M | ||
| Q4 24 | $201.2M | $10.1M | ||
| Q3 24 | $106.5M | $-25.2M | ||
| Q2 24 | $-444.6M | $72.3M |
| Q1 26 | — | 4.8% | ||
| Q4 25 | 92.0% | 1.9% | ||
| Q3 25 | 92.8% | 10.7% | ||
| Q2 25 | 93.5% | 7.9% | ||
| Q1 25 | 93.0% | 9.0% | ||
| Q4 24 | 92.5% | 9.4% | ||
| Q3 24 | 92.4% | 8.5% | ||
| Q2 24 | 92.7% | 14.5% |
| Q1 26 | 23.7% | — | ||
| Q4 25 | 22.3% | -9.4% | ||
| Q3 25 | 32.5% | 4.8% | ||
| Q2 25 | 43.6% | 2.0% | ||
| Q1 25 | 19.5% | 2.7% | ||
| Q4 24 | 25.6% | 2.8% | ||
| Q3 24 | 12.8% | 1.0% | ||
| Q2 24 | -45.8% | 8.3% |
| Q1 26 | 23.8% | — | ||
| Q4 25 | 19.9% | -8.6% | ||
| Q3 25 | 31.1% | 2.6% | ||
| Q2 25 | 33.3% | -0.2% | ||
| Q1 25 | 15.0% | 0.1% | ||
| Q4 24 | 17.1% | 0.6% | ||
| Q3 24 | 9.4% | -1.6% | ||
| Q2 24 | -42.6% | 4.4% |
| Q1 26 | $1.47 | $-0.73 | ||
| Q4 25 | $1.46 | $-1.25 | ||
| Q3 25 | $2.11 | $0.37 | ||
| Q2 25 | $2.04 | $-0.01 | ||
| Q1 25 | $0.80 | $0.01 | ||
| Q4 24 | $0.90 | $0.10 | ||
| Q3 24 | $0.54 | $-0.21 | ||
| Q2 24 | $-2.04 | $0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $192.2M |
| Total DebtLower is stronger | — | $3.0B |
| Stockholders' EquityBook value | $5.6B | $1.7B |
| Total Assets | $7.3B | $7.4B |
| Debt / EquityLower = less leverage | — | 1.73× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $192.2M | ||
| Q4 25 | $3.1B | $167.6M | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.7B | $175.6M | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $987.3M | — |
| Q1 26 | — | $3.0B | ||
| Q4 25 | — | $2.8B | ||
| Q3 25 | — | $3.0B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | — | $2.8B |
| Q1 26 | $5.6B | $1.7B | ||
| Q4 25 | $5.2B | $1.8B | ||
| Q3 25 | $4.7B | $2.0B | ||
| Q2 25 | $4.2B | $2.0B | ||
| Q1 25 | $3.7B | $2.0B | ||
| Q4 24 | $3.4B | $2.0B | ||
| Q3 24 | $3.2B | $2.1B | ||
| Q2 24 | $3.0B | $2.1B |
| Q1 26 | $7.3B | $7.4B | ||
| Q4 25 | $7.0B | $7.3B | ||
| Q3 25 | $6.3B | $7.6B | ||
| Q2 25 | $5.8B | $7.7B | ||
| Q1 25 | $5.7B | $7.7B | ||
| Q4 24 | $5.4B | $7.6B | ||
| Q3 24 | $5.0B | $7.5B | ||
| Q2 24 | $4.7B | $7.7B |
| Q1 26 | — | 1.73× | ||
| Q4 25 | — | 1.55× | ||
| Q3 25 | — | 1.52× | ||
| Q2 25 | — | 1.52× | ||
| Q1 25 | — | 1.50× | ||
| Q4 24 | — | 1.34× | ||
| Q3 24 | — | 1.34× | ||
| Q2 24 | — | 1.31× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INCY
Segment breakdown not available.
OLN
| Chlor Alkali Products and Vinyls | $756.9M | 48% |
| Winchester | $470.5M | 30% |
| Epoxy | $355.6M | 22% |
